Richard Hughen’s first entrepreneurial experience was as Managing Director at e-learning startup LearnWare, where he says his “addiction” to startups began in earnest. The former manager at Abbott Diagnostics, Cordis and Johnson & Johnson enjoyed LearnWare for the very reason that entrepreneurs usually get hooked: building something from scratch is exhilarating
California Life Sciences Association (CLSA), the trade association representing California’s life sciences industry, today commended the U.S. Senate’s confirmation of Alex M. Azar, II as the new secretary of the U.S. Department of Health and Human Services (HHS).
Paragon Bioservices has plans to expand to new space over the next two years to help companies develop and manufacture biopharmaceuticals.
Researchers with the Johns Hopkins University School of Medicine developed a new blood test able to screen for eight types of cancers.
REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced an agreement with FUJIFILM Diosynth Biotechnologies (FUJIFILM) for the manufacture of REGENXBIO’s lead product candidates, including RGX-314 and RGX-501, which will support late-stage clinical development and early commercialization. This partnership builds on the foundation of REGENXBIO’s internal manufacturing and process development capabilities.
New York City is doubling down on its long-discussed, never-realized dream of building a biotech hub to rival South San Francisco and Boston. The latest iteration of the dream comes backed by a $500 million financing package and a goal to quadruple the amount of R&D space in the city.
After nearly a year, venture capitalists nabbed their first U.S. acquisition for more than a billion dollars. And it wasn’t a tech startup. Nor was it a company on the list of known unicorns. And it had nothing to do with blockchain.
Accelerate Baltimore™ is an initiative of the ETC (Emerging Technology Centers), Baltimore’s award winning incubator, and The Abell Foundation. In its first six years, we have invested $1,025,000 in 34 companies. We are now in our seventh year with 6 innovative technology startup companies who are working to accelerate their ideas to market.
Our goal is to close the gap between innovative ideas and getting to market by providing seed capital, resources, mentors, potential partners and a collaborative community. Accelerate Baltimore runs once a year, will you be ready for our next cohort?
Paragon Bioservices (Paragon), the leading private equity-backed biologics contract development and manufacturing organization (CDMO) with proven expertise in gene therapy and next-generation vaccines, announces the expansion of a new process development and cGMP manufacturing facility located conveniently near Baltimore/Washington International Thurgood Marshall (BWI) Airport. Growing need for broad gene therapy manufacturing capacity from its current and future client base is driving the company’s investment in this new facility, which the company expects will include commercial manufacturing capabilities in 18 to 24 months.
Analysts had forecast a blockbuster year for life science mergers and acquisitions as the lower tax rate for repatriated cash kicks-in and Big Pharma continues its hunt for late-stage assets.
